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Abstract
Background: France is the European country with the lowest level of confidence in vaccines. Measurement of
patients’ acceptability towards a future therapeutic HIV vaccine is critically important. Thus, the aim of this study
was to evaluate patients’ acceptability of a future therapeutic HIV vaccine in a representative cohort of French
patients living with HIV-AIDS (PLWHs).
Methods: This multicentre study used quantitative and qualitative methods to assess PLWHs’ opinions and their
potential acceptance of a future therapeutic HIV vaccine. Cross-sectional study on 220 HIV-1 infected outpatients,
aged 18–75 years.
Results: The participants’ characteristics were similar to those of the overall French PLWH population. Responses
from the questionnaires showed high indices of acceptance: the mean score for acceptability on the Visual Analog
Scale VAS was 8.4 of 10, and 92% of patients agreed to be vaccinated if a therapeutic vaccine became available.
Acceptability depended on the expected characteristics of the vaccine, notably the duration of its effectiveness:
44% of participants expected it to be effective for life. This acceptance was not associated with socio-demographic,
clinical (mode of contamination, duration of disease), quality of life, or illness-perception parameters. Acceptability
was also strongly correlated with confidence in the treating physician.
Conclusion: The PLWHs within our cohort had high indices of acceptance to a future therapeutic HIV vaccine.
Trial registration: This study was retroactively registered on ClinicalTrials.gov with ID: NCT02077101 in February 21,
2014.
Keywords: HIV, Therapeutic vaccine, Acceptability, Acceptance, Confidence
Background
In developed countries, where effective antiretroviral
treatment (ART) is available, people living with HIV
(PLWH) have acquired a long-term positive prognoses
[1]. HIV infection is now a chronic disease but there is a
patient demand for a cure. There is currently intense re-
search into the development of a HIV therapeutic vac-
cine to obtain sustained ART-free HIV remission. It is
expected that, in the future, PLWH will benefit from
such vaccines [2–4].
There is also intense research on an HIV vaccine to
prevent disease transmission and possibly eradicate the
pandemic [5–7]. HIV-preventive and HIV-therapeutic
vaccine research benefit from each other’s results and
improve our understanding of the mechanisms of im-
mune protection against HIV. Six efficacy trials that
have been conducted to date, and only one, the RV144
Thai trial of ALVAC/gp120, showed a modest protective
efficacy [8]. But these results has provided important les-
sons for future strategies towards a cure for HIV [9].
The WHO Strategic Advisory Group of Experts
(SAGE) on Immunization has recognized that reserva-
tions about vaccines (vaccine hesitancy) are a growing
global problem [10, 11].
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Anticipation of the “acceptability” of vaccines by the
public has become an increasingly important factor in
the development of new vaccines [12].
Many studies have shown the crucial role of General
Practitioners (GPs) in promoting and proposing prevent-
ive vaccination [13]. GPs are the gatekeepers of the
French health system, and are usually consulted by their
patients regarding vaccination issues [13–18]. France is
the European country with a highest vaccine hesitancy
[19]. In the French general population, refusal of vaccin-
ation has become frequent, particularly for the hepatitis
B and for the influenza vaccine especially as many inter-
net sites report frightening consequences of vaccination.
In 2009, 24% of French GPs had a “vaccination hesi-
tancy” profile [20–22] and remains high.
Attitudes to vaccination are a continuum ranging from
total acceptance to complete refusal [23].
In the general population, the determinants of accept-
ance of HIV-preventive vaccination have been studied
[24–26]. Newman et al. in 2010, reported in a meta-ana-
lysis a high acceptability of HIV preventive vaccination,
which was correlated with vaccine effectiveness and dur-
ation of protection. Barriers were correlated with fear of
side effects and of syringes [24].
There is only one publication on the willingness to
participate in HIV Therapeutic Vaccine Trials among
HIV-Infected Patients on ART in China. This study
showed high acceptability [27].
In France, due to the complex attitudes of the general
population, we considered important to study if the fu-
ture HIV therapeutic vaccines will be acceptable when
they will become available.
To this effect, the Representations and Acceptability of
a Therapeutic HIV Vaccine (RAVVIH) study was de-
signed to explore the perceptions of therapeutic HIV
vaccines in a cohort of HIV outpatients.
Methods
The objective of this study was to assess the acceptability
of a future HIV therapeutic vaccine in HIV-positive out-
patients aged 18–75 years. Univariate and multivariate
analyses were conducted to find the factors correlated to
HIV vaccine acceptability.
Study design
The RAVVIH study was a prospective cross-sectional
conducted in three hospitals. The three infectious dis-
ease departments that participated in this study were se-
lected to be representative of French AIDS-care centers.
One is a private tertiary hospital (Hôpital Foch), Hôpital
Louis Mourier is a University hospital in the Paris sub-
urbs, and CHR d’Orleans is a public provincial hospital.
Study participants
Between December 2013 and May 2014, consecutive
outpatients were solicited during their biannual HIV visit
to their HIV physician. Eligibility criteria were: being
aged between 18 and 75 years, being infected with
HIV-1 and having French medical insurance coverage.
Patients who did not speak French language were ex-
cluded. Questionnaire administration and interviews
took place at the patient’s care hospital.
Methods
Quantitative study
Patients completed three self-administered question-
naires: two that had previously been validated (Brief
IPQ-R [28] and PROQOL-HIV [29]) and a specific ques-
tionnaire on vaccination: the RAVVIH questionnaire;
they also scored a Visual Analog Scale (VAS) of
acceptability.
The Brief Illness Perception Questionnaire-Revised
(Brief IPQ-R) is a nine-item scale designed to rapidly as-
sess the cognitive and emotional representations of ill-
ness. The Brief IPQ-R uses a single-item approach to
assess perception on a 0–10 response scale. It comprises
items on cognitive perceptions of illness: consequences,
timeline, personal control, treatment control and iden-
tity. This questionnaire explores patients’ own beliefs
about their condition [30].
The Patient-Reported Outcomes Quality Of Life spe-
cific HIV instrument (PROQOL-HIV) comprises 43
items, dealing with eight themes that dominate the expe-
riences of HIV patients living in the ART era: General
health perceptions, social relationships, emotions, en-
ergy/fatigue, sleep, cognitive functioning, physical and
daily activities, coping, future and treatment’s impact. It
was developed simultaneously across nine countries, in
accordance with rigorous international standards [31, 32].
Scores for each dimension range from 0 to 100 (100 = best
QoL). A four-dimension summary scoring scheme was re-
cently proposed [33] which has been used in our study:
physical health and symptoms (PHS), health concerns and
mental distress (HCMD), social and intimate relationships
(REL), and treatment-related impact (TRT).
The RAVVIH questionnaire includes 50 items regard-
ing factors identified in several preventive acceptance
studies. These items were selected by the RAVVIH study
group (DZ, SD, MD) and tested by five PLWHs. It
covers three main themes on vaccination: knowledge,
representation and acceptability. Among these 50 items,
28 are 5-point Likert-type questions ranging from 1
(strongly disagrees) to 5 (strongly agrees), the others re-
quiring dichotomous answers.
The Visual Analogue Scale (VAS) of acceptability is a
horizontal analogue scale graduated from 0 (“Whatever
my situation, I will never accept a therapeutic vaccine”)
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to 10 (“I see no problem in using a therapeutic vaccine
as soon as one becomes available”), on which the patient
expresses his/her level of agreement with the proposal
using a check mark.
Qualitative study
A review of the literature was performed to identify im-
portant HIV-vaccine acceptance determinants: doctor
confidence, knowledge, perceptions of illness, secrecy,
quality of life (Qol). These determinants were used as
the main topics in the interview guide, 20 patients who
did not participate in the quantitative study were inter-
viewed. Semi-structured face−to−face interviews were
performed by a trained psychologist (IP) until data satur-
ation was obtained [33]. The interviews, of 45–60 min
duration, were recorded and transcribed verbatim. A tri-
angulation analysis was performed by two experienced
researchers (IA and LB). Open coding was performed
within a framework predefined by the themes in the
interview guide. A common list was used and enriched
for further analysis, which was carried out manually.
Study outcomes
The primary outcome was the therapeutic HIV-vaccine
acceptability on the Visual Analog Scale (VAS). Second-
ary outcomes were factors associated with vaccine ac-
ceptability according to the questionnaires, answers to
the Brief Illness Perception Scale (Brief IPQ-R), and to
the PROQOL-HIV questionnaire.
Statistical analyses
A preliminary power analysis indicated that a total of
200 participants was required to estimate a mean score
VAS with a margin of error (half width of a 95% confi-
dence interval) less than 0.5 point assuming a standard
deviation of 1 point. The distribution of acceptability
scores was summarized using means, medians, standard
deviations and interquartile ranges for continuous vari-
ables and counts and proportions for categorical data.
Two-group comparisons were performed using the
Mann–Whitney test in cases of continuous outcomes
and Pearson’s chi-square test in cases of categorical vari-
ables. Multivariate analysis was also used to explore re-
sponses to the 50 items of the RAVVIH questionnaire.
Pearson’s correlations were used to reduce the 28
Likert-type questions to a subset of variables that correl-
ate above 0.25 to the therapeutic HIV-vaccine accept-
ability VAS. Principal-component analysis was carried
out on this subset of 28 variables (the Likert-type re-
sponses being considered as continuous). Only complete
cases with no missing responses were included for this
analysis. All statistical tests were two-tailed with a sig-
nificance level at 5%. The R software (The R Foundation,
Vienna, Austria) was used for all statistical analyses.
Ethics
All subjects provided their written consent prior to the
study. Questionnaires and interviews were fully anonym-
ous. A favorable ethical opinion was obtained from the rele-
vant French Ethics Committee (IDRCB 2013-A01344–41).
Clinical trial registration
This study was registered retroactively on ClinicalTrials.
gov with ID: NCT0207710.
Results
On the global sample (qualitative and quantitative) N =
220, there were 5 missing data on sex.
Table 1 shows the clinical characteristics of the 215
(mean age ± SD: 48 ± 12).
70% (N = 151) were men, 59% of them (N = 88) being
men who have sex with men; 21 patients (10%) were
intravenous drug users.
26% of patients were at the CDC clinical stage C, but
did not have any associated opportunistic infection since
several years before the study.
Almost all patients (96%) were taking ART and 92%
had an undetectable viral load.
Quantitative study
Social patient characteristics
Majority of the sample had french nationality (80%), 58%
completed high school and 88% had a current job.
VAS of therapeutic vaccine acceptability
The VAS score for the acceptability of a future thera-
peutic vaccine was (mean ± SD) 8.4 ± 2.2. Nearly half of
the participants (46%) gave a score of 10. Those who re-
ported in the RAVVIH questionnaire that they would
accept therapeutic vaccination in the future had an aver-
age score of 8.9 ± 1.5 whereas those who were negative
(“no” and “don’t know”) had a mean score of 5.0 ± 2.7
(Wilcoxon test, p < 0.001).
RAVVIH questionnaire
Sixty− 7 % of all patients considered their recommended
vaccine coverage to be complete. Only 18% reported a
history of side−effects from their last vaccine: mainly
local pain, redness and swelling.
In the patients’ medical files, we found that immunization
coverage for hepatitis B, diphtheria, tetanus and poliomyel-
itis was high at 75%. Immunization coverage was much
lower for influenza (15%) and pneumococcus (21%).
The willingness to receive a therapeutic HIV vaccine
was high (91%) if the referent HIV clinician recom-
mended it, but 71% of participants feared possible side
−effects. The mode of administration (syringe) was not a
barrier for these participants (86%).
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Willingness to participate in a therapeutic HIV-vaccine
clinical trial was high (74%); only 9% of patients gave a
negative response, and 17% had no opinion.
Patients would consider stopping ongoing ART if the
efficacy of the therapeutic vaccine on HIV viral load was
demonstrated to be between 85 and 100%.
Forty− 4 % of patients contended that lifelong cessa-
tion of ART was the only acceptable endpoint. Three to
six months without taking ART was considered a satis-
factory therapeutic goal by 40% of patients and 9 to 12
months was preferred by a minority (12%).
The more frequently expected benefits were stopping
the treatment burden of daily pills (93%) and not to be a
risk for HIV transmission to partner or children (84%).
Most participants agreed to be vaccinated if a thera-
peutic vaccine became available (92%). Thirty percent
(57 patients) thought that “doctors do not tell all the
truth about vaccines”.
Detailed results are provided in Table 2, which also
shows those questionnaire Likert−type scales that were
correlated to the acceptability VAS.
Evaluation of disease burden with the brief IPQ-R
questionnaire
Participants were worried by the duration of their dis-
ease (How long do you think your illness will con-
tinue?) and by the impact of their symptoms (How
much do you experience symptoms from your ill-
ness?)(mean ± SD: 2.1 ± 2.6). Answers were more posi-
tive concerning their antiretroviral treatment, and
their understanding of their disease.
In general, PLWHs scored high on ‘treatment control’
(9.1 ± 1.6) (How much do you think your treatment can
help your illness?) and ‘concern’ (8.1 ± 2.5) (How con-
cerned are you about your illness?).
Evaluation of patients’ Qol with the PROQOL-HIV
questionnaire
Except for the HCMD dimension, average scores were
superior to 70 (on a 100 points scale), and 50% of the
participants scored between 60 and 90 points, indicating
that their Qol was intermediate to good. The lower
HCMD score shows participants to be more bothered by
stigma and sexual issues. The quality of their social rela-
tionships was considered satisfactory.
Multivariate analyses
Among the 28 Likert-type questions in the RAVVIH
questionnaire, nine were correlated (Pearson’s r > 0.25)
to VAS scores (Table 2).
A principal component analysis (PCA) on 149 partici-
pants with no missing responses gave a primary dimen-
sion that accounted for 35% of total variance, while the
second dimension accounted for 13% of variance. The
first dimension (Fig. 1) is clearly bidimensional opposing
vaccine efficacy and recommendation by GP to control,
DNA, ART side−effects, disease worsening and disease
Table 1 Clinical characteristics of patients n=215
Female
N = 64
Male
N = 151
Total
N = 215
Age [years] 44 (11) 50 (12) 48 (12)
Disease duration [years] 13 (8.9) 15 (8.9) 14 (8.9)
HIV infection transmission risk group
Heterosexuals 89% (54) 27% (41) 45% (95)
MSM 0% (0) 59% (88) 42% (88)
Injecting drug users 8% (5) 11% (16) 10% (21)
Others 3% (2) 3% (5) 3% (7)
Duration of ART [years] 10 (7.3) 11 (7.0) 11 (7.0)
CDC clinical stage
A 60% (35) 66% (80) 64% (115)
B 12% (7) 7% (9) 9% (16)
C 28% (16) 26% (31) 26% (47)
HIV viral load below detection limit 89% (56) 93% (138) 92% (194)
CD4 [cell count/mm] 631(286) 672 (296) 661 (286)
Co-morbidities
Chronic hepatitis B (AgHbs+) 8% (5) 3% (5) 5% (10)
Hepatitis C (positive HCV serology) 12% (8) 15% (22) 14% (30)
HBV + HCV 2% (1) 1% (2) 1% (3)
Treated Diabetes 3% (2) 9% (13) 7% (15)
Treated Hypertension 20% (13) 30% (45) 27% (58)
Cancer 6% (4) 9% (13) 8% (17)
Vaccination coverage
HBV vaccination:
up to date 64% (38) 80% (116) 75% (154)
not up to date 20% (12) 9% (13) 12% (25)
don’t know 15% (9) 11% (16) 12% (25)
Diphtheria-tetanus-inactivated poliovirus vaccination dTp:
up to date 67% (43) 75% (113) 73% (156)
not up to date 14% (9) 14% (21) 14% (30)
don’t know 19% (12) 11% (16) 13% (28)
Pneumococcal vaccination:
updated 16% (10) 15% (22) 15% (32)
not up to date 62% (40) 70% (101) 67% (141)
don’t know 22% (14) 15% (22) 17% (36)
Influenza vaccination:
up to date 19% (12) 23% (32) 21% (44)
not up to date 72% (46) 69% (98) 70% (144)
don’t know 9% (6) 8% (12) 9% (18)
Numerical variables are summarized using mean (SD); categorical variables are
summarized using proportions (counts); MSM, men who have sex with men
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duration. The second dimension is one−dimensional and
lumps together recommendations by GPs, ART con-
straints, vaccine development and side−effects. Individ-
ual factor scores from the first dimension of PCA were
significantly correlated to the VAS on acceptability of a
future therapeutic vaccine (Pearson r = 0.59, 95% CI
[0.47;0.68], P < 0.005).
With respect to the IPQ-R, there is little difference be-
tween the total participants’ score according to their
response on the acceptability of the therapeutic vaccine:
“Yes”, 33.1 ± 10.6; “No”, 34.0; “Do not know”, 34.8 ± 9.6.
By grouping the responses “No” and “Do not know”,
there was no significant difference between the two
groups of respondents (Wilcoxon test, p = 0.721).
The quality of life scores for each of the 4 dimensions
of the PROQOL-HIV questionnaire according to the re-
sponse on the acceptability of the therapeutic vaccine
are summarized in Fig. 1. For the only patient who
Table 2 Answers to the Likert scales of the RAVVIH questionnaire
Question N Strongly
agree
Agree Un-certain Disagree Strongly
disagree
VAS
correlation
My treating general practitionner understands my disease 196 128 (65.3) 40 (20.4) 20 (10.2) 4 (2.0) 4 (2.0) 0.001
Generally we can trust the doctors 198 103 (52.0) 80 (40.4) 11 (5.6) 4 (2.0) – 0.174
Doctors don’t tell us everything about vaccines 196 15 (7.7) 42 (21.4) 51 (26.0) 61 (31.1) 27 (13.8) 0.035
I have a good general knowledge on vaccination 196 19 (9.7) 86 (43.9) 51 (26.0) 26 (13.3) 14 (7.1) 0.153
I think vaccines are effective 195 106 (54.4) 79 (40.5) 9 (4.6) 1 (0.5) – 0.356a
For vaccines to be effective several doses are important 200 169 (84.5) 26 (3.0) 4 (2.0) – 1 (0.5) 0.241
For vaccines, I do not trust health public authorities 193 16 (8.3) 43 (22.3) 65 (33.7) 51 (26.4) 18 (9.3) 0.177
Health public authorities tend to hide informations 193 25 (13.0) 54 (28.0) 62 (32.1) 41 (21.2) 11 (5.7) 0.122
I do not trust pharmaceutical companies 196 20 (10.2) 63 (32.1) 60 (30.6) 38 (19.4) 15 (7.7) 0.226
One day, I believe they will find a vaccine to cure the HIV virus 199 130 (65.3) 60 (30.2) 9 (4.5) – – 0.275a
I understand what is a HIV therapeutic vaccine 197 115 (58.4) 63 (32.0) 17 (8.6) 2 (1.0) – 0.101
I will agree if my doctor recommends it to me 195 134 (68.7) 46 (23.6) 7 (3.6) 5 (2.6) 3 (1.5) 0.500a
I prefer to stay on ART it is safer because I already know it 174 21 (12.1) 32 (18.4) 51 (29.3) 42 (24.1) 28 (16.1) 0.403a
If an effective therapeutic vaccine against HIV was available
my sexual life would change
200 60 (30.0) 35 (17.5) 49 (24.5) 36 (18.0) 20 (10.0) 0.046
If an effective therapeutic vaccine against HIV was available
I would have more sexual partners
198 8 (4.0) 13 (6.6) 37 (18.7) 60 (30.3) 80 (40.4) 0.013
If an effective therapeutic vaccine against HIV was available
I would be less likely to use condoms
198 26 (13.1) 26 (13.1) 27 (13.6) 56 (28.3) 63 (31.8) 0.005
If an effective therapeutic vaccine against HIV was available
I would have more satisfaction in your sexual life?
196 49 (25.0) 40 (20.4) 49 (25.0) 34 (17.3) 24 (12.2) 0.142
I am worried by the possible side effects (of an HIV therapeutic vaccine) 198 58 (29.3) 82 (41.4) 32 (16.2) 19 (9.6) 7 (3.5) 0.321a
As the vaccine is administered with a needle this would be an
obstacle for me
197 5 (2.5) 2 (1.0) 21 (10.7) 42 (21.3) 127 (64.5) 0.166
I am worried because we do not still know the actual long-term
efficiency of this vaccine
198 40 (20.2) 78 (39.4) 43 (21.7) 21 (10.6) 16 (8.1) 0.427a
I am worried that the vaccine can make me even sicker 197 29 (14.7) 34 (17.3) 61 (31.0) 45 (22.8) 28 (14.2) 0.316a
It worries me to know that a part of the vaccine is made with viral DNA 197 18 (9.1) 20 (10.2) 69 (35.0) 45 (22.8) 45 (22.8) 0.294a
I am worried because with the vaccine I cannot control what I
take compared with the daily taking of antiretrovirals
196 16 (8.2) 30 (15.3) 51 (26.0) 45 (23.0) 54 (27.6) 0.387a
I expect a therapeutic HIV vaccine to improve my social life 197 94 (47.7) 45 (22.8) 31 (15.7) 13 (6.6) 14 (7.1) 0.065
I expect a therapeutic vaccine to allow me not to contaminate
my close family/friends
198 130 (65.7) 37 (18.7) 17 (8.6) 8 (4.0) 6 (3.0) 0.040
I expect a therapeutic HIV vaccine to facilitate my professional life 191 63 (33.0) 35 (18.3) 53 (27.7) 20 (10.5) 20 (10.5) 0.051
I expect a therapeutic HIV vaccine to improve my sentimental life 198 86 (43.4) 50 (25.3) 39 (19.7) 14 (7.1) 9 (4.5) 0.024
I expect a therapeutic HIV vaccine to improve the daily constraints
of taking treatement
197 137 (69.5) 47 (23.9) 9 (4.6) 1 (0.5) 3 (1.5) 0.253a
Counts (percentage)
asignificanly correlated to the VAS acceptability score
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answered “No”, it is noteworthy that with the exception
of the PHS dimension, the quality of life is greatly worse
compared to other patients, especially on the COG di-
mension (22.5 vs 60.5 ± 23.3). The quality of life scores
of patients who answered “Do not know” do not differ
significantly from those who answered “yes”.
It should be noted that the total IPQ-R score remains
well correlated with PROQOL-HIV dimension scores:
PHS, r = − 0.533, p < 0.001; COG, r = − 0.525, p < 0.001;
REL, r = − 0.588, p < 0.001; TRT, r = − 0.387, p < 0.001.
No difference of the acceptability of the future vaccine
was found related to sociodemographic characteristics: gen-
der (Pearson chi-2, p = 0.487, age (Welch t test, p = 0.521),
level of education (undergraduate vs graduate, p = 0.688),
or the socioprofessional status (stable vs. precarious em-
ployment p = 0.916). Similarly, year of HIV diagnosis, mode
of transmission and ART duration did not influence the
acceptability.
Acceptability is presented considering different con-
cepts emerging from factorial analysis. Some arrows are
overlapping like ART constrains and HIV vaccine as well
as long term efficiency and disease worsening. There is
no correlation between the acceptability of the future
HIV vaccine and the patients quality of life (Fig. 2).
Qualitative analyses
The mean age of 20 participants was 46 years [range:
23–66], 13 were male and 14 had a CDC stage A. All
patients were on ART and 95% had an undetectable viral
load (Table 3).
i) Doctor–Patient relationship
Patients considered their relationship to their phys-
ician as satisfactiory. They had “a complete trust” or “ab-
solute trust” in them. Patients put forward medical
support, empathy and psychological and social care:
“Coming to my hospital here is a support, there is always
someone who will listen to me, wanting to know what I
think”; “my doctor is always available, he made me over-
come many fears regarding HIV”.
ii) Perceptions of general vaccination
Half of the interviewees had a very favorable opinion
and very strong positive feelings on vaccines, citing them
as “a benefit for humanity”. Other patients did not
understood the difference between mandatory and rec-
ommended vaccines. Only one patient had a negative
view of vaccination and admitted that vaccines fright-
ened her.
iii) Knowledge about vaccines
The majority of patients (12/20) admitted having lim-
ited knowledge about vaccines. They were unable to give
Fig. 1 Acceptability and quality of life
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a definition of therapeutic vaccination. Even when patients
thought they had some knowledge, they were unable to
explain the mode of action of therapeutic vaccine. One pa-
tient said “Instead of taking medication, you get vacci-
nated” or “It’s several associated drugs. I’m not sure”.
iv) Fear of injections
Only a few patients (6/20) expressed fear of injection.
One stated it was a “phobia” for her.
v) Future characteristics of HIV therapeutic vaccines
The vaccination injection schedule was a key factor for
most patients. The minimal acceptable interval between
doses of HIV therapeutic vaccine was 6 months. A pa-
tient said “Every year is OK, every month is more incon-
venient”; another one: “the longer effective, the better it
is”. The future efficacy of therapeutic HIV vaccination
on HIV viral load must be as effective as their ongoing
ART: the minimal efficacy for undetectable viral load
was between 80 and 100%.
vi) Expected benefits
Patients’ expected a therapeutic vaccine to reduce the
daily burden of treatment with minimal side−effects;
easing guilt feelings about transmitting HIV to others
was also a major incentive.
A minority of patients (4/20) expected no change from
the vaccine: “the disease is still there”, “I am sick, I am
sick, and nothing will change”.
vii) Vaccination barriers
Several patients (8/20) feared the possible side−effects
but were also concerned by the possibility of ineffective-
ness “If I’m not sure about the vaccine”.
viii)Hope of a cure
Fig. 2 Multivariate analysis of the HIV vaccine acceptability. The angle formed by two vectors is proportional to the correlation between the two
variables. Thus, the smaller the angle, the more the variables are correlated with one another; two vectors whose angle is approximately 180 °
indicates a strong negative correlation; finally, two vectors whose angle is 90 ° reflects and absence of correlation between the two variables
associated with these vectors
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The majority of patients (13/20) hoped for a cure, and
believed that a therapeutic vaccine to cure HIV would
be found in the future “One day I think we will find a
vaccine to cure the HIV virus”.
Discussion
To our knowledge, our study is the first to provide infor-
mation from a western country on the acceptability by
PLWHs for a future therapeutic HIV vaccine. Our study
shows high indices of acceptance: the mean score for ac-
ceptability on the VAS was 8.4, and 92% of patients agreed
to be vaccinated if a therapeutic vaccine becomes available.
HIV therapeutic acceptance depended on the expected
characteristics of the vaccine, notably its duration of ef-
fectiveness: 44% of participants demanded the vaccine to
be effective for life.
In other diseases, the situation is similar to HIV; there
are several therapeutic vaccines in clinical development:
HBV, HCV, HPV papilloma virus [34–36].
The only one therapeutic vaccine available since 2011 in
the USA, is a prostate cancer therapeutic vaccine [37]. For
this vaccine, there has not been publication about the ac-
ceptability. Similarly, there is no published acceptability ana-
lysis for vaccine candidates in other chronic viral diseases.
The only comparison we could make, is with efficient
prophylactic vaccines, for which the acceptability is
reported as rather low in France. That is why this study
brings important focus.
The participants’ vaccine coverage was higher than those
described in Mohseni et al. study [38]. Health-related Qol
scores of the RAVVIH study patients were comparable to
those reported in the VESPA 2 study [39].
Acceptance was not associated with socio-demographic,
clinical (mode of contamination, duration of disease),
or Qol and illness-perception parameters possibly be-
cause the expected benefits of future therapeutic HIV
vaccines were so high that they overshadowed differ-
ences in patients’ characteristics. The acceptability
was strongly correlated with the confidence in the
treating physician. Even some patients that believed
the doctors in general would not tell all the truth
about vaccines, would have a strong trust in their
physician and would agree to their advices.
Compared to those reported by patients suffering from
diabetes or asthma [28], the Brief IPQ-R scores of our
patients show that ‘identity’ was much less affected for
PLWHs (2.1 ± 2.6) than for diabetic (4.6 ± 2.8) or asth-
matic (4.5 ± 2.3) patients. However, PLWHs scored gen-
erally higher on ‘treatment control’ (9.1 ± 1.6 vs. 8.0 ± 2.3
[diabetes] and 7.9 ± 2.0 [asthma]) and ‘concern’ (8.1 ± 2.5
vs. 7.0 ± 3.1 [diabetes] and 4.6 ± 2.8 [asthma]) dimen-
sions of the Brief IPQ-R. This suggests that treatment
Table 3 Characteristics of the 20 interviewees
Patient Gender M/F Duration of HIV diagnosis CDC ART ART regimen
1 F 17 A RAL/LPV BID
2 M 23 A TDF/FTC/DRV/r OD
3 M 18 C TDF/FTC/EFV OD
4 M 32 A TDF/FTC/RAL BID
5 M 9 C TDF/FTC/EFV OD
6 M 6 A TDF/FTC/RPV OD
7 F 35 A TDF/FTC/RAL OD
8 M 32 C TDF/FTC/DRV/r OD
9 M 25 A TDF/FTC OD
10 M 33 A ABC/3TC/EFV OD
11 M 14 A TDF/FTC/ETR OD
12 M 7 A TDF/FTC/RPV OD
13 F 33 A TDF/FTC/DRV/r OD
14 F 18 C TDF/FTC/LPV/r BID
15 M 34 B ABC/3TC/EFV OD
16 M 32 A TDF/FTC/DRV/r BID
17 M 33 C TDF/FTC/DRV/r BID
18 F 22 A ABC/3TC/ETV OD
19 F 9 A DRV/r OD
20 F 7 A TDF/FTC/EFV OD
Abbreviations: ART active antiretroviral therapy, 3TC lamivudine, FTC emtricitabine, ABC abacavir, TDF tenofovir, ETV etravirine, RPV rilpivirine, EFV efavirenz, DRV
darunavir, LPV lopinavir, r ritonavir, RAL raltegravir, OD once a day, BID twice a day
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burden may be highly flustering to PLWHs currently on
ART. Their scores on the ‘consequence’ dimension were
comparable to those reported by patients suffering from
diabetes.
In the field of future preventive HIV vaccines, New-
man et al. [25] have already reported that acceptability is
correlated with perceived effectiveness on transmission,
possible side−effects, dose regimen and time intervals
between doses [25].
However, while therapeutic vaccines are a rapidly grow-
ing new technology in medical science (several studies are
ongoing on the efficacy of therapeutic vaccines, mainly for
cancer [34]) however, studies on the representations and
acceptability of these vaccines are lacking.
Only one study in Chinese PLWH (Dong et al. [27])
has adressed the willingness to participate in a thera-
peutic HIV-vaccine clinical trial and shown high rates of
acceptance.
Our study has some limitations. The study has been
proposed to all consecutive subjects, unhappily the num-
ber and the reasons for non-participation has not been re-
corded in a registry, but globally one quarter of patients
did not accepted to participate, and mostly due to lack of
time. This study is about the theoretical acceptability and
it may be possible that in a real life decision situation
some patients would decide differently. However the Pa-
tient’ self-Reported Outcome has showed its validity on
different levels and is now considered as a valid endpoint
by Health Authorities. The three clinics participating in
this study may be more actively encouraging updating
preventive vaccination coverage than other hospitals.
Concerning the HBV vaccination 40% of patients were up
to date versus 73% in our sample, concerning the
Diphtheria-tetanus-inactivated poliovirus vaccination dTp:
56,2% of patients were up to date versus 72% in our sam-
ple. In fact, the uptake of immunization coverage of our
study population was somewhat higher than the figures
observed for other French hospitals [38].
The results from the RAVVIH study may not be dir-
ectly applicable to other countries with health systems
differing from France. The study does not assess some
important dimensions of acceptance, such as cost as in
France, ART is fully reimbursed.
Further, French guidelines for immunization for
PLWHs recommend diphtheria, tetanus, poliomyelitis,
pneumococcus, influenza and hepatitis B vaccines.
Conclusion
This study explored the perceptions regarding a future
therapeutic HIV vaccine in a representative sample of
French PLWHs. PLWHs were receptive to the idea of
receiving a therapeutic HIV vaccine. The vaccine’s char-
acteristics and confidence in their treating clinician were
acceptability’s key factors.
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